In terms of clinical implications, rs3219489/MUTYH may serve as a genetic marker for cancer risk assessment, especially in specific populations, and could influence the effectiveness of radiochemotherapy in patients with non-small-cell lung cancer (NSCLC) [51]. This evidence concerns the gene MUTYH and non-small cell lung carcinoma.